Spots Global Cancer Trial Database for MAGE-A4ᶜ¹º³²T for Multi-Tumor

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: MAGE-A4ᶜ¹º³²T for Multi-Tumor

Official Title: Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Study ID: NCT03132922

Conditions

Urinary Bladder Cancer

Melanoma

Head and Neck Cancer

Ovarian Cancer

Non-Small Cell Lung Cancer

Esophageal Cancer

Gastric Cancer

Synovial Sarcoma

Myxoid Round Cell Liposarcoma

Gastroesophageal Junction

Interventions

Autologous genetically modified MAGE-A4ᶜ¹º³²T cells

Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation

Study Description

Brief Summary: This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.

Detailed Description: